161 related articles for article (PubMed ID: 19715447)
1. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.
Ding C; Cicuttini F; Li J; Jones G
Expert Opin Investig Drugs; 2009 Oct; 18(10):1457-66. PubMed ID: 19715447
[TBL] [Abstract][Full Text] [Related]
2. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
4. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of blocking IL-6 receptor.
Mima T; Nishimoto N
Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab: the first interleukin-6-receptor inhibitor.
Sebba A
Am J Health Syst Pharm; 2008 Aug; 65(15):1413-8. PubMed ID: 18653811
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
9. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
Febbraio MA; Rose-John S; Pedersen BK
Clin Pharmacol Ther; 2010 Apr; 87(4):396-8. PubMed ID: 20305672
[TBL] [Abstract][Full Text] [Related]
10. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
13. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis.
Plushner SL
Ann Pharmacother; 2008 Nov; 42(11):1660-8. PubMed ID: 18957621
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
17. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?
Moots RJ; Ostör AJ; Isaacs JD
Expert Opin Investig Drugs; 2009 Nov; 18(11):1687-99. PubMed ID: 19715449
[TBL] [Abstract][Full Text] [Related]
18. Anticytokine therapy in autoimmune diseases.
Nishimoto N; Kishimoto T; Yoshizaki K
Intern Med; 1999 Feb; 38(2):178-82. PubMed ID: 10225680
[TBL] [Abstract][Full Text] [Related]
19. The effects of interleukin-6 signal blockade on immune system, reproductive and skeletal development in juvenile mice.
Sakurai T; Takai R; Bürgin H; Shioda A; Sakamoto Y; Amano J; Grimm HP; Richter WF; Higuchi Y; Chiba S; Kawamura A; Suzuki M; Müller L
Birth Defects Res B Dev Reprod Toxicol; 2013 Apr; 98(2):170-82. PubMed ID: 23529913
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy using IL-6 receptor as the target].
Nishimoto N
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
